Prenatal Screening Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Prenatal Screening Market Report Overview

The prenatal screening market size was valued at $642.3 million in 2022. In most countries, maternal serum screening and ultrasound remain standard-of-care for screening of pregnant women for chromosome aneuploidies and other birth defects. If these tests are positive, then prenatal diagnosis is typically performed via either amniocentesis or chorionic villus sampling (CVS). However, both amniocentesis and CVS are invasive techniques that have a risk of fetal death and miscarriage.

NIPT is performed using cell-free DNA from maternal blood, which is amplified and sequenced. Due to the sequencing process, NIPT is more expensive than maternal serum screening methods and this represents a major barrier in its widespread clinical adoption. In general, higher cost, low fetal fraction, and the occurrence of false positives are some of the challenging factors in the implementation of NIPT.

Prenatal Screening Market Outlook, 2022-2033 ($ Million)

For more insights into the prenatal screening market forecast, download a free report sample

The report is built to visualize quantitative market trends within in vitro diagnostics therapeutic area therapeutic areas. The model discusses in detail the impact of COVID-19 on the Prenatal screening market for the year 2020 and beyond. Each of the covered 39 country’s color-coded and fully sourced market models are equipped with epidemiology-based indications with procedure volumes.

Prenatal Screening Market Dynamics

The incidence of Down Syndrome is increasing globally and awareness about disease and prenatal screening. Sales of Prenatal screening device depends upon disease incidence, live births rate, and number of pregnant women. Governments in many countries are taking initiatives to implement tests and offer fully funded prenatal screening to all pregnant women. The introduction of Non-Invasive Prenatal Testing (NIPT) has reduced the uptake of serum screening and invasive tests in many countries.

Prenatal Screening Market Segments

The prenatal screening market comprises key segments including Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests. In 2022, the Non-invasive prenatal testing (NIPT) segment dominated the prenatal screening market share.

Prenatal Screening Market Analysis by Segments, 2022 (%)

For more insights into the prenatal screening market segments, download a free report sample

Prenatal screening Market Segmentation by Regions

The key regions in the prenatal screening market are North America, Europe, Asia Pacific, South Central America, and the Middle East and Africa. North America has the largest share of the prenatal screening market. The number of prenatal screening is expected to grow in the forecast years throughout North America. This increase is mainly due to a growing preference for minimally invasive techniques.

The US and Canada both have large elderly populations, with approximately 40% of their total populations aged 50 years or older. These aging populations not only boost the size of the current arthroscopy shavers market but also provide strong potential for growth. In North America, there has been an increase in sports-related injuries due to the popularity of sports such as football, basketball, baseball, and ice hockey. In the US alone, there have been around 2.5 million sports-related injuries.

Prenatal screening Market Analysis by Regions, 2022 (%)

For more insights into the prenatal screening market segments, download a free report sample

Prenatal Screening Market - Competitive Landscape

Some of the leading companies in the prenatal screening market are Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc, Abbott Laboratories, Siemens Healthineers AG, Quidel Corp, Thermo Fisher Scientific Inc, and Tosoh Corp among others. Illumina Inc held the largest share of the prenatal screening market in 2022.

Prenatal Screening Market Analysis by Companies, 2022 (%)

To know more about the leading companies in the prenatal screening market, download a free report sample

Segments Covered in the Report

Prenatal Screening Segments Outlook (Value, $ Million, 2015-2033)

• Alpha-Fetoprotein (AFP) Tests
• Free Beta Human Chorionic Gonadotropin (hCG) Tests
• Inhibin A Tests
• Non-invasive prenatal testing (NIPT)
• Pregnancy Associated Plasma Protein A (PAPP-A) Tests
• Total Human Chorionic Gonadotropin (hCG) Tests
• Unconjugated Estriol (uE3) Tests

Prenatal Screening Regional Outlook (Value, $ Million, 2015-2033)

• North America
• Europe
• Asia Pacific
• South Central America
• Middle East and Africa

Key Inclusions of the market model are –

• Currently marketed Prenatal Screening and evolving competitive landscape –
• Insightful review of the key industry trends.
• Annualized total Prenatal Screening market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights –

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Prenatal Screening market.
• Competitive dynamics insights and trends provided for Prenatal Screening market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, PerkinElmer Inc, Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, Thermo Fisher Scientific Inc, Tosoh Corp, Myriad Genetics Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This report provides:

• Currently marketed prenatal screening and evolving competitive landscape.
• Insightful review of the key industry trends.
• Annualized total prenatal screening market revenue by segment and market outlooks.
• Granular data on total procedures, units, average selling prices, and market values by segment.
• Global, regional, and country-level market-specific insights.
• Qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the prenatal screening market.
• Competitive dynamics insights and trends provided for the prenatal screening market.
• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific MedTech regulatory landscape.

Reasons to Buy

The model will enable you to –

• Understand the impact of COVID-19 on the prenatal screening market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Prenatal screening market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the prenatal screening market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific prenatal screening market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.